Synergistic anticancer mechanisms of curcumol and paclitaxel in triple-negative breast cancer treatment may involve down-regulating ZBTB7A expression via the NF-B signaling pathway. The gene discussed is ZBTB7A; the disease is triple-negative breast carcinoma.